Your browser doesn't support javascript.
The incidence of anosmia in patients with laboratory-confirmed COVID 19 infection in India: An observational study.
Kumar, Vinod; Singla, Sapna; Gupta, Nishkarsh; Bharati, Sachidanand Jee; Garg, Rakesh; Pandit, Anuja; Vig, Saurabh; Mishra, Seema; Bhatnagar, Sushma.
  • Kumar V; Department of Oncoanaesthesia and Palliative Medicine, AIIMS, Delhi, India.
  • Singla S; Department of Oncoanaesthesia and Palliative Medicine, AIIMS, Delhi, India.
  • Gupta N; Department of Oncoanaesthesia and Palliative Medicine, AIIMS, Delhi, India.
  • Bharati SJ; Department of Oncoanaesthesia and Palliative Medicine, AIIMS, Delhi, India.
  • Garg R; Department of Oncoanaesthesia and Palliative Medicine, AIIMS, Delhi, India.
  • Pandit A; Department of Oncoanaesthesia and Palliative Medicine, AIIMS, Delhi, India.
  • Vig S; Department of Oncoanaesthesia and Palliative Medicine, AIIMS, Delhi, India.
  • Mishra S; Department of Oncoanaesthesia and Palliative Medicine, AIIMS, Delhi, India.
  • Bhatnagar S; Department of Oncoanaesthesia and Palliative Medicine, AIIMS, Delhi, India.
J Anaesthesiol Clin Pharmacol ; 37(1): 51-56, 2021.
Article in English | MEDLINE | ID: covidwho-1206403
ABSTRACT
BACKGROUND AND

AIMS:

Acute loss of smell or anosmia is a common and sometimes the only symptom observed in patients with coronavirus disease-2019 (COVID-19). The objective of the study was to determine the prevalence, time of onset, and duration of anosmia in patients with COVID-19 infection and the association of anosmia with other symptoms and eosinophil count. MATERIAL AND

METHODS:

Two hundred patients with laboratory-confirmed COVID-19 infection, who were asymptomatic or mildly symptomatic were assessed for olfaction with a nonirritant odor. The presence of anosmia was recorded, and a questionnaire integrating the anosmia reporting tool was filled. Patients with anosmia/hyposmia were followed telephonically at 7 and 14 days for resolution of anosmia and other symptoms. The presence of anosmia was correlated with eosinophil count.

RESULTS:

Of the 200 COVID-19 patients, 87% were symptomatic. More than half of the patients had fever (56%). Anosmia was observed in 30% of the patients and hyposmia in 4% of patients. In 41% of the patients, olfactory loss was reported before diagnosis. The mean duration of anosmia was 7.8 (± 5) days; 97% of patients recovered with a resolution of symptoms within 2 weeks. Ageusia was the most commonly and significantly associated symptom with anosmia (66%, n = 45) followed by sore throat (41%), and rhinorrhea (28%). The symptoms in both the sexes were comparable. Absolute eosinophil count of <40/µL was observed in 59 patients (29.5%) and an absolute eosinophil count of 0 in 17 patients (8.5%). Among the 68 anosmic patients, 36 (47%) patients had eosinopenia, which was statistically significant.

CONCLUSION:

Anosmia is an early and sometimes the only symptom in approximately one-third of the patients with COVID-19 infection. Eosinophil count should be checked in anosomic patient with suspicion of COVID-19 infection. Objective tools for olfactory and gustatory assessment should be brought into practice for early and prompt diagnosis to control the spread of the disease.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Language: English Journal: J Anaesthesiol Clin Pharmacol Year: 2021 Document Type: Article Affiliation country: Joacp.JOACP_653_20

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Language: English Journal: J Anaesthesiol Clin Pharmacol Year: 2021 Document Type: Article Affiliation country: Joacp.JOACP_653_20